Blocking Tnf-Alpha By Combination Of Tnf-Alpha- And Tnfr-Binding Cyclic Peptide Ameliorates The Severity Of Tnbs-Induced Colitis In Rats

Bingjiao Yin,Xin Hu,Jing Wang,Huifang Liang,Xiaoyan Li,Nin Niu,Baihua Li,Xiaodan Jiang,Zhuoya Li
DOI: https://doi.org/10.1016/j.ejphar.2011.01.046
IF: 5.195
2011-01-01
European Journal of Pharmacology
Abstract:Tumor necrosis factor alpha (TNF-alpha) has been implicated in the pathogenesis of Crohn's disease. TNF antagonists are effectively used to treat these patients, although the efficiency of different antagonists varies. In the present study we combined INF-alpha binding cyclic peptide (TBCP) and TNFR1 binding cyclic peptide (TRBCP) to treat TNBS-induced colitis in rats for one week. The symptoms of colitis including bloody diarrhea, rectal prolapse, and a profound and sustained weight loss were significantly ameliorated and the colon inflammatory damage, both macroscopic and histological scores, MPO activity, and NO production were markedly decreased in rats by neutralization of INF-alpha and blocking TNFR1, as compared with those in rats treated with irrelevant peptide or normal saline (P < 0.05). The transcripts of IL-1 beta and IL-8, and the protein expression of TNF-alpha in rats treated with both TBCP and TRBCP were also down-regulated (P < 0.05), while these proinflammatory cytokines remained unchanged in rats treated with irrelevant peptide or normal saline. These findings suggest that the combination of INF-alpha- and TNFR1-binding peptide effectively improves the symptoms of TNBS-induced colitis and alleviates colonic pathological damages in rats. This combination may be a potent candidate for clinical treatment of the inflammatory bowel disease. (C) 2011 Elsevier B.V. All rights reserved.
What problem does this paper attempt to address?